TScan Therapeutics, Inc. Forecasted to Post Q2 2024 Earnings of ($0.23) Per Share (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Research analysts at Lifesci Capital issued their Q2 2024 earnings per share estimates for shares of TScan Therapeutics in a report released on Monday, May 13th. Lifesci Capital analyst S. Slutsky expects that the company will earn ($0.23) per share for the quarter. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.01) per share. Lifesci Capital also issued estimates for TScan Therapeutics' Q3 2024 earnings at ($0.24) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.08. TScan Therapeutics had a negative return on equity of 56.89% and a negative net margin of 653.50%. The business had revenue of $7.21 million during the quarter, compared to analyst estimates of $2.94 million.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Tuesday. Wedbush reiterated an "outperform" rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Monday. Finally, Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Monday.

TScan Therapeutics Stock Down 0.7 %

TScan Therapeutics stock traded down $0.06 during mid-day trading on Wednesday, reaching $8.93. The stock had a trading volume of 350,461 shares, compared to its average volume of 184,967. The firm has a market capitalization of $427.57 million, a PE ratio of -7.02 and a beta of 0.91. TScan Therapeutics has a fifty-two week low of $1.93 and a fifty-two week high of $9.36. The stock's 50-day simple moving average is $7.52 and its 200-day simple moving average is $6.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51.

Institutional Trading of TScan Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TCRX. abrdn plc purchased a new stake in shares of TScan Therapeutics during the 4th quarter valued at $1,166,000. Pale Fire Capital SE purchased a new stake in TScan Therapeutics during the third quarter worth about $42,000. Letko Brosseau & Associates Inc. purchased a new position in TScan Therapeutics in the third quarter valued at about $83,000. Vanguard Group Inc. grew its holdings in TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company's stock valued at $14,357,000 after purchasing an additional 20,000 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new stake in shares of TScan Therapeutics in the first quarter valued at $1,685,000. Hedge funds and other institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.